Search for
COVID Guide
Jobs
Events
Rev1 Labs
Blog
Entrepreneur Toolkit
Menu
Entrepreneurs
Diversity, Equity and Inclusion Grant
Mentor Program
Internship Program
Corporates
Investors
Portfolio
About
Team
Partners
Get Started
Home
Entrepreneurs
Corporates
Investors
Portfolio
About
Get Started
COVID Guide
Jobs
Events
Rev1 Labs
Blog
Entrepreneur Toolkit
Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
By
Rev1 Staff
on
10/06/2016
Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
Comments are closed.
